List of Clario CTMS Customers
Clario
1818 Market St. Suite 2600,
Philadelphia, 19103, PA,
United States
Philadelphia, 19103, PA,
United States
1 800-515-2279
Professional Services
7200
$965M
Since 2010, our global team of researchers has been studying Clario CTMS customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Clario CTMS for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Clario CTMS for Clinical Trial Management include: Thermo Fisher Scientific, a United States based Life Sciences organisation with 125000 employees and revenues of $42.88 billion, FutureMeds, a United Kingdom based Life Sciences organisation with 397 employees and revenues of $36.0 million, Fate Therapeutics, a United States based Life Sciences organisation with 181 employees and revenues of $14.0 million and many others.
Contact us if you need a completed and verified list of companies using Clario CTMS, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Clario CTMS customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Fate Therapeutics | Life Sciences | 181 | $14M | United States | Clario | Clario CTMS | Clinical Trial Management | 2022 | n/a |
In 2022, Fate Therapeutics onboarded Clario CTMS for Clinical Trial Management, initiating a companywide implementation focused on study setup and operational control. The implementation effort was led through the Clinical Systems Operations function during a Mar 2022 to Mar 2023 program phase, positioning Clario CTMS to manage study design, study setup, and operational tracking for all Fate studies entered into the system.
The deployment included formal validation and onboarding of Clario CTMS, with the Clinical Systems Operations Manager acting as subject matter expert for CTMS, IRT, and Veeva applications. Selection activities prior to onboarding included risk assessments, cost comparisons, and long term forecasting, and configuration work emphasized study configuration, user provisioning workflows, and the creation of interactive global user training modules and practices to support adoption.
The Clario CTMS implementation was executed alongside parallel systems work for Veeva Vault 22R2 and IRT vendors Suvoda and Almac, with vendor management responsibilities spanning system updates, change control, and budget invoice reviews. Operational coverage extended across clinical teams and Fate management, and the team created and maintained the lifecycle for approximately 1,000 global internal and external user accounts across CTMS, IRT, and Veeva systems.
Governance and process control were formalized through validation documentation, business process artifacts, and supervised change control for IRT and CTMS changes. The Clinical Systems Operations function owned study setup governance, vendor coordination for system changes, and ongoing account administration, embedding the Clario CTMS into established clinical operations processes.
|
 |
FutureMeds | Life Sciences | 397 | $36M | United Kingdom | Clario | Clario CTMS | Clinical Trial Management | 2024 | n/a |
In 2024 FutureMeds implemented Clario CTMS for Clinical Trial Management to support clinical operations and pharmacy functions across its trial portfolio. The deployment was positioned to centralize study coordination tasks performed by Clinical Study Coordinators and Clinical Trials Pharmacists and to standardize investigational medicinal product handling workflows across sites including activity in Madrid. The project alignment reflects FutureMeds scale and life sciences operations, with configuration choices proportional to a mid market sponsor and site network. Clario CTMS was used as the primary system for study orchestration and operational control.
Clario CTMS was configured to provide study setup and site management capabilities, visit scheduling and tracking, investigational medicinal product receipt storage dispensing and traceability, and a document management layer for the investigator s file and essential documents. The implementation included eCRF linkage and query management workflows to support data entry and resolution by site staff. Functional automation emphasized scheduling coordination for patient testing sample submission and monitoring visit preparation.
The Clario CTMS instance was integrated with existing clinical platforms that FutureMeds site staff referenced during daily operations, including iMedidata Rave, Veeva Vault, Suvoda, Epro and Endpoint to enable data exchange and document flow between operational systems. Operational coverage spanned coordination of multiple trials in different therapeutic areas, site level pharmacy procedures for preparation and reconstitution of medication according to protocol, and facilitation of communications between site investigators and CROs and sponsors. Users explicitly included Clinical Study Coordinator I and Clinical Trials Pharmacist roles as primary operators of the platform.
Governance and process controls were aligned to ICH GCP E6 R2 Good Clinical Practice requirements, with explicit workflows for verification of storage conditions investigational medicinal product accountability and audit ready maintenance of the investigator s file. The rollout emphasized procedural adherence for monitoring visits and protocol driven medication handling rather than large scale technical customization. Documentation and role based access controls were established to support compliance and routine monitoring activity.
|
 |
Thermo Fisher Scientific | Life Sciences | 125000 | $42.9B | United States | Clario | Clario CTMS | Clinical Trial Management | 2024 | n/a |
In 2024, Thermo Fisher Scientific implemented Clario CTMS as a centralized platform in the Clinical Trial Management category. The deployment targeted clinical monitoring and trial management workflows to support clinical research associates who perform site monitoring, assess protocol and regulatory compliance, and manage monitoring documentation in accordance with GCP and global SOPs.
Clario CTMS was configured to deliver core Clinical Trial Management capabilities including study and site management, visit scheduling and monitoring visit documentation, source data verification tracking, protocol deviation logging, and centralized trial documentation management. Configuration emphasized study-level templates, role-based access for monitoring staff, and standardized monitoring visit artifacts aligned to internal SOPs.
Operational coverage centered on Clinical Operations and Monitoring teams, enabling site initiation, routine monitoring, and closeout activities while centralizing artifacts that support safety and regulatory review workflows. Integration touchpoints were provisioned to exchange clinical operational data with internal clinical data services and downstream safety and regulatory processes using standard API and data export patterns.
Governance and rollout focused on change control, role-specific training for CRAs on Clario CTMS workflows, and enforcement of monitoring plans through CTMS audit and reporting features, ensuring alignment with global SOPs and GCP requirements. The program emphasized configuration governance and training to maintain consistent documentation practices during site visits and across monitoring activities.
|
Showing 1 to 3 of 3 entries
Buyer Intent: Companies Evaluating Clario CTMS
ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Clario CTMS. Gain ongoing access to real-time prospects and uncover hidden opportunities. Companies Actively Evaluating Clario CTMS for Clinical Trial Management include:
- CRISIL, a India based Banking and Financial Services organization with 3900 Employees
- Bank of America, a United States based Banking and Financial Services company with 213000 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||
FAQ - APPS RUN THE WORLD Clario CTMS Coverage
Clario CTMS is a Clinical Trial Management solution from Clario.
Companies worldwide use Clario CTMS, from small firms to large enterprises across 21+ industries.
Organizations such as Thermo Fisher Scientific, FutureMeds and Fate Therapeutics are recorded users of
Clario CTMS for Clinical Trial Management.
Companies using Clario CTMS are most concentrated in Life Sciences, with adoption spanning over 21 industries.
Companies using Clario CTMS are most concentrated in United States and United Kingdom, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Clario CTMS across Americas, EMEA, and APAC.
Companies using Clario CTMS range from small businesses with 0-100 employees - 0%, to mid-sized firms with 101-1,000 employees - 66.67%, large organizations with 1,001-10,000 employees - 0%, and global enterprises with 10,000+ employees - 33.33%.
Customers of Clario CTMS include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.
Contact APPS RUN THE WORLD to access the full verified Clario CTMS customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Clinical Trial Management.